Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?
- 1 December 2000
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 2 (1) , 20-25
- https://doi.org/10.1007/s11883-000-0091-3
Abstract
The inhibition of cellular proliferation, the restoration of endothelial activity, the inhibition of platelet reactivity, and an antioxidant potential are only a few examples of pleiotropic effects of statins. This review analyzes the current knowledge on the pleiotropic properties of this class of drugs and examines the relevant data that support the presence of these effects in vivo. The favorable outcome of major trials of statins has indicated that pleiotropic factors indeed play a role in cardiovascular protection. In addition, recent data indicate that many pleiotropic effects influence mechanisms that belong to the extravascular compartment, as well. Perhaps, some of these properties may eventually justify additional indications for statins and improve the treatment of other diseases, including inflammation and cancer.Keywords
This publication has 62 references indexed in Scilit:
- Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)The American Journal of Cardiology, 1999
- Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53Oncogene, 1998
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Vastatins Inhibit Tissue Factor in Cultured Human MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemiaAtherosclerosis, 1996
- Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)Journal of the American College of Cardiology, 1995
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophagesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway productsAtherosclerosis, 1991
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart diseaseJAMA, 1984